Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.

Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM.

Clin Cancer Res. 2017 Nov 15;23(22):6888-6892. doi: 10.1158/1078-0432.CCR-17-1317. Epub 2017 Aug 8.

2.

Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma.

Danielsen M, Kjaer A, Wu M, Martineau L, Nosrati M, Leong SP, Sagebiel RW, Miller JR III, Kashani-Sabet M.

Am J Nucl Med Mol Imaging. 2016 Sep 22;6(5):277-285. eCollection 2016.

3.

BPTF transduces MITF-driven prosurvival signals in melanoma cells.

Dar AA, Majid S, Bezrookove V, Phan B, Ursu S, Nosrati M, De Semir D, Sagebiel RW, Miller JR 3rd, Debs R, Cleaver JE, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2016 May 31;113(22):6254-8. doi: 10.1073/pnas.1606027113. Epub 2016 May 16.

4.

The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.

Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, Sun V, Tong S, Leong SP, Minor D, Billings PR, Soroceanu L, Debs R, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

J Natl Cancer Inst. 2015 Feb 23;107(5). pii: djv034. doi: 10.1093/jnci/djv034.

5.

Prognostic impact of PHIP copy number in melanoma: linkage to ulceration.

Bezrookove V, De Semir D, Nosrati M, Tong S, Wu C, Thummala S, Dar AA, Leong SPL, Cleaver JE, Sagebiel RW, Miller JR 3rd, Kashani-Sabet M.

J Invest Dermatol. 2014 Mar;134(3):783-790. doi: 10.1038/jid.2013.369. Epub 2013 Sep 4.

6.

A patient-centered methodology that improves the accuracy of prognostic predictions in cancer.

Kashani-Sabet M, Sagebiel RW, Joensuu H, Miller JR 3rd.

PLoS One. 2013;8(2):e56435. doi: 10.1371/journal.pone.0056435. Epub 2013 Feb 27. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/2db613f0-06cc-47e7-bde2-7c61bc792bb9.

7.

Analysis of sentinel lymph node positivity in patients with thin primary melanoma.

Venna SS, Thummala S, Nosrati M, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

J Am Acad Dermatol. 2013 Apr;68(4):560-567. doi: 10.1016/j.jaad.2012.08.045. Epub 2012 Nov 19.

PMID:
23182069
8.

Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis.

De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G, Venna S, Rangel J, Climent J, Meyer Tamg├╝ney TM, Thummala S, Tong S, Leong SP, Haqq C, Billings P, Miller JR 3rd, Sagebiel RW, Debs R, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):7067-72. doi: 10.1073/pnas.1119949109. Epub 2012 Apr 17.

9.

Sunbeds and sunlamps: who used them and their risk for melanoma.

Fears TR, Sagebiel RW, Halpern A, Elder DE, Holly EA, Guerry D 4th, Tucker MA.

Pigment Cell Melanoma Res. 2011 Jun;24(3):574-81. doi: 10.1111/j.1755-148X.2011.00842.x. Epub 2011 Mar 29.

10.

Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center.

Shoo BA, Sagebiel RW, Kashani-Sabet M.

J Am Acad Dermatol. 2010 May;62(5):751-6. doi: 10.1016/j.jaad.2009.09.043. Epub 2010 Mar 19.

PMID:
20303612
11.

A multimarker prognostic assay for primary cutaneous melanoma.

Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW.

Clin Cancer Res. 2009 Nov 15;15(22):6987-92. doi: 10.1158/1078-0432.CCR-09-1777. Epub 2009 Nov 3.

12.

A multi-marker assay to distinguish malignant melanomas from benign nevi.

Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR 3rd, Sagebiel RW.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6268-72. doi: 10.1073/pnas.0901185106. Epub 2009 Mar 30.

13.

Rapidly lethal metastatic melanoma arising from a large congenital melanocytic naevus.

Wei CH, Shoo BA, Zedek DC, Kashani-Sabet M, Sagebiel RW, Leong SP.

BMJ Case Rep. 2009;2009. pii: bcr09.2008.0981. doi: 10.1136/bcr.09.2008.0981. Epub 2009 Feb 27.

14.

Novel role for RGS1 in melanoma progression.

Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

Am J Surg Pathol. 2008 Aug;32(8):1207-12. doi: 10.1097/PAS.0b013e31816fd53c.

PMID:
18580492
15.

Osteopontin as a molecular prognostic marker for melanoma.

Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

Cancer. 2008 Jan 1;112(1):144-50.

16.

Reproductive risk factors for cutaneous melanoma in women: a case-control study.

Lea CS, Holly EA, Hartge P, Lee JS, Guerry D 4th, Elder DE, Halpern A, Sagebiel RW, Tucker MA.

Am J Epidemiol. 2007 Mar 1;165(5):505-13. Epub 2006 Dec 8.

PMID:
17158470
17.

Prognostic significance of extent of ulceration in primary cutaneous melanoma.

Grande Sarpa H, Reinke K, Shaikh L, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

Am J Surg Pathol. 2006 Nov;30(11):1396-400.

PMID:
17063079
18.

Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.

Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

J Clin Oncol. 2006 Oct 1;24(28):4565-9.

PMID:
17008696
19.

Genes and pathways downstream of telomerase in melanoma metastasis.

Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, Sagebiel RW, Cleaver JE, Haqq C, Debs RJ, Blackburn EH, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11306-11. Epub 2006 Jul 17.

20.

Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.

Fears TR, Guerry D 4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA.

J Clin Oncol. 2006 Aug 1;24(22):3590-6. Epub 2006 May 25.

PMID:
16728488
21.

Persistent microscopic primary melanoma in patients presenting with node-positive disease.

Reinke KA, Sagebiel RW, Allen RE, Kashani-Sabet M.

J Am Acad Dermatol. 2005 Nov;53(5):906-8. No abstract available.

PMID:
16243158
22.

The role of microsatellites as a prognostic factor in primary malignant melanoma.

Shaikh L, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd, Kashani-Sabet M.

Arch Dermatol. 2005 Jun;141(6):739-42.

PMID:
15967920
23.

Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Leong SP, Kashani-Sabet M, Desmond RA, Kim RP, Nguyen DH, Iwanaga K, Treseler PA, Allen RE Jr, Morita ET, Zhang Y, Sagebiel RW, Soong SJ.

World J Surg. 2005 Jun;29(6):683-91.

PMID:
15895193
24.

The gene expression signatures of melanoma progression.

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7. Epub 2005 Apr 15.

25.

Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.

Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry D 4th, Hartge P, Struewing JP, Hogg D, Halpern A, Sagebiel RW, Tucker MA.

Cancer. 2004 Dec 15;101(12):2809-16.

26.

Diet and melanoma in a case-control study.

Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D 4th, Holly EA, Sagebiel RW, Potischman N.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1042-51.

27.

NF-kappa B in the vascular progression of melanoma.

Kashani-Sabet M, Shaikh L, Miller JR 3rd, Nosrati M, Ferreira CM, Debs RJ, Sagebiel RW.

J Clin Oncol. 2004 Feb 15;22(4):617-23.

PMID:
14966085
28.

Delayed harvesting of sentinel lymph nodes after previous wide local excision of extremity melanoma.

Leong SP, Thelmo MC, Kim RP, Gokhale R, Rhee JY, Achtem TA, Morita E, Allen RE Jr, Kashani-Sabet M, Sagebiel RW.

Ann Surg Oncol. 2003 Mar;10(2):196-200.

PMID:
12620917
29.

Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk.

Fears TR, Bird CC, Guerry D 4th, Sagebiel RW, Gail MH, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA.

Cancer Res. 2002 Jul 15;62(14):3992-6.

30.

Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).

Zettersten E, Sagebiel RW, Miller JR 3rd, Tallapureddy S, Leong SP, Kashani-Sabet M.

Cancer. 2002 Feb 15;94(4):1049-56.

31.

Tumor vascularity in the prognostic assessment of primary cutaneous melanoma.

Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd.

J Clin Oncol. 2002 Apr 1;20(7):1826-31.

PMID:
11919240
32.

Vascular involvement in the prognosis of primary cutaneous melanoma.

Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd.

Arch Dermatol. 2001 Sep;137(9):1169-73.

PMID:
11559212
33.

Micrometastasis to in-transit lymph nodes from extremity and truncal malignant melanoma.

Thelmo MC, Morita ET, Treseler PA, Nguyen LH, Allen RE Jr, Sagebiel RW, Kashani-Sabet M, Leong SP.

Ann Surg Oncol. 2001 Jun;8(5):444-8.

PMID:
11407520
34.

Evaluation of sentinel lymph node status in spindle cell melanomas.

Thelmo MC, Sagebiel RW, Treseler PA, Morita ET, Nguyen LH, Kashani-Sabet M, Leong SP.

J Am Acad Dermatol. 2001 Mar;44(3):451-5.

PMID:
11209114
35.

Fine needle aspiration in the diagnosis of metastatic melanoma.

Rodrigues LK, Leong SP, Ljung BM, Sagebiel RW, Burnside N, Hu Tl, Ng BW, Miller JR 3rd, Kashani-Sabet M.

J Am Acad Dermatol. 2000 May;42(5 Pt 1):735-40.

PMID:
10775847
36.

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial.

Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SP, Small EJ.

Cancer. 1999 Nov 15;86(10):2160-5.

PMID:
10570447
37.

Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma.

Leong SP, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE Jr, Sagebiel RW, Glassberg AB, Lowenberg DW, Hayes FA.

J Immunother. 1999 Mar;22(2):166-74.

PMID:
10093041
38.

Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma.

Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR 3rd, Leong SP.

Arch Dermatol. 1998 Aug;134(8):983-7.

PMID:
9722728
39.

Optimal selective sentinel lymph node dissection in primary malignant melanoma.

Leong SP, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE Jr, Morita ET, el-Kadi M, Epstein HD, Kashani-Sabet M, Sagebiel RW.

Arch Surg. 1997 Jun;132(6):666-72; discussion 673.

PMID:
9197861
40.

Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.

Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D 4th, Clark WH Jr.

JAMA. 1997 May 14;277(18):1439-44.

PMID:
9145715
41.

The multidisciplinary melanoma center.

Sagebiel RW.

Surg Clin North Am. 1996 Dec;76(6):1433-9. Review.

PMID:
8977561
42.

Unusual variants of melanoma: fact or fiction?

Sagebiel RW.

Semin Oncol. 1996 Dec;23(6):703-8.

PMID:
8970590
43.

Cutaneous melanoma in women: anatomic distribution in relation to sun exposure and phenotype.

Cress RD, Holly EA, Ahn DK, LeBoit PE, Sagebiel RW.

Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):831-6.

44.

Who needs zebras? Comments on desmoplastic melanoma.

Sagebiel RW.

J Am Acad Dermatol. 1995 May;32(5 Pt 1):800-2. No abstract available.

PMID:
7722026
45.

Nevus counting as a risk factor for melanoma: comparison of self-count with count by physician.

Lawson DD, Moore DH 2nd, Schneider JS, Sagebiel RW.

J Am Acad Dermatol. 1994 Sep;31(3 Pt 1):438-44.

PMID:
8077469
46.

Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi.

Schneider JS, Moore DH 2nd, Sagebiel RW.

Arch Dermatol. 1994 Aug;130(8):1002-7.

PMID:
8053695
47.

Inter-observer variability among pathologists' evaluation of malignant melanoma: effects upon an analytic study.

Krieger N, Hiatt RA, Sagebiel RW, Clark WH Jr, Mihm MC Jr.

J Clin Epidemiol. 1994 Aug;47(8):897-902.

PMID:
7730893
48.

A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi.

Piepkorn MW, Barnhill RL, Cannon-Albright LA, Elder DE, Goldgar DE, Lewis CM, Maize JC, Meyer LJ, Rabkin MS, Sagebiel RW, et al.

J Am Acad Dermatol. 1994 May;30(5 Pt 1):707-14.

PMID:
8176008
49.

The pathology of melanoma as a basis for prognostic models: the UCSF experience.

Sagebiel RW.

Pigment Cell Res. 1994 Apr;7(2):101-3.

PMID:
8066014
50.

Melanoma risk factors and atypical moles.

Williams ML, Sagebiel RW.

West J Med. 1994 Apr;160(4):343-50. Review.

Supplemental Content

Loading ...
Support Center